Novartis Investigative Site

Leuven, Vlaams Brabant 3000

3 studies enrolling now · 9 studies all time

What they study most

ALK-positive NSCLC, Amyotrophic Lateral Sclerosis (ALS), Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Early Breast Cancer, Generalized Myasthenia Gravis, Healthy Volunteers, Pulmonary Arterial Hypertension, Hidradenitis Suppurativa, Secondary Progressive Multiple Sclerosis (SPMS)

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) — Running, not enrolling
• Iptacopan in Patients With ANCA Associated Vasculitis — Running, not enrolling
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer — Running, not enrolling
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling